Integrated computational and *Drosophila* cancer model platform captures previously unappreciated chemicals perturbing a kinase network

Peter Man-Un Ung[1]†, Masahiro Sonoshita[2]†, Alex P. Scopton[3], Arvin C. Dar[3], Ross L. Cagan[2]*, Avner Schlessinger[1]*

[1]Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029.
[2]Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
[3]Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

* Corresponding authors. E-mail:

ross.cagan@mssm.edu

avner.schlessinger@mssm.edu

† These authors contributed equally to this work.

ABSTRACT

Drosophila provides an inexpensive and quantitative platform for measuring whole animal drug response. A complementary approach is virtual screening, where chemical libraries can be efficiently screened against protein target(s). Here, we present a unique discovery platform integrating structure-based modeling with *Drosophila* biology and organic synthesis. We demonstrate this platform by developing chemicals targeting a *Drosophila* model of Medullary Thyroid Cancer (MTC) with disease-promoting kinase network activated by mutant dRet^{M955T}. Structural models for kinases relevant to MTC were generated for virtually screening to identify initial hits that were dissimilar to known kinase inhibitors yet suppressed dRet^{M955T}-induced oncogenicity. We then combined features from the hits and known inhibitors to create a 'hybrid' molecule with improved dRet^{M955T} phenotypic outcome. Our platform provides a framework to efficiently explore novel chemical spaces, develop compounds outside of the current inhibitor chemical space, and ''correct'' cancer-causing signaling networks to improve disease prognosis while minimizing whole body toxicity.

Protein kinases play a key role in cell signaling and disease networks and make up major therapeutic targets. The limited capacity to test large number of compounds exploring diverse chemical scaffolds, coupled with the low translatability of *in vitro* kinase inhibition into whole animal efficacy, effectively constrain the chemical space of the known kinase inhibitors (KIs). Thus, obtaining optimal KIs at clinically relevant therapeutic levels is challenging, despite extensive academic and industry effort.

To expand the number of kinase inhibitors, a variety of platforms have recently emerged as useful tools for compound screening. *Drosophila melanogaster* (fruit fly) provides an inexpensive and efficient biological platform for cancer drug screening, capturing clinically relevant compounds[1, 2, 3]. For example, *Drosophila* was used to help validate vandetanib as a useful treatment for medullary thyroid cancer[4] (MTC). As a screening platform, *Drosophila* offers several advantages: First, flies and humans share similar kinome and kinase-driven signaling pathways[5], facilitating the use of flies to predict drug response in humans[1, 6]. Second, the ease of breeding and the short (~10 day) life cycle of *Drosophila* make it possible to carry out efficient mid-throughput chemical screening in a biological system. Third, the screening readout provides a quantitative animal-based measurement of structure-activity relationships (SAR), and further provides information on the therapeutic potential or toxicity of the tested compounds: measurable parameters include survival and multiple phenotypic indicators that depend on kinase activity.

One key limitation of *Drosophila*-based mid-throughput screening platform is that it cannot explore very large chemical libraries[7], such as the ZINC library which has over 750 million purchasable compounds[8]. In contrast, structure-based virtual screening is a fast and inexpensive computational method that can screen large compound libraries, a useful approach to identify unique chemical probes[9]. If the structure of the protein is unknown, virtual screening can be performed against the homology models of the target constructed based on experimentally determined structures. However, the automated construction of homology models—with sufficient accuracy for virtual screening for multiple targets simultaneously and the application of molecular docking to signaling networks—remains challenging in particular for highly dynamic targets such as kinases[10, 11] and would benefit from a readily accessible whole animal platform.

RET is a receptor tyrosine kinase associated with multiple roles in development and homeostasis. Activation of RET by the mutation M918T (analogous to *Drosophila* M955T) is associated with MTC[12, 13]. Transgenic *Drosophila* expressing the dRet^{M955T} isoform show key aspects of transformation, including proliferation and some aspects of metastasis[6, 14]. Genetic modifier screens with dRet^{M955T} flies led to the identification of multiple RET pathway genetic 'suppressors' and 'enhancers', loci that when reduced in activity improve or worsen the disease phenotype, respectively. These functional mediators of RET-dependent transformation include members of the Ras/ERK and PI3K pathways as well as regulators of metastasis such as SRC[6, 15].

Oral administration of the FDA approved, structurally related multi-kinase inhibitor analogs sorafenib and regorafenib, along with additional structural analogs, partially rescued *dRet^{M955T}*-induced oncogenicity in *Drosophila*[1, 15]. Sorafenib class inhibitors are classified as 'type-II' KIs that bind the kinase domain in its inactive state[16], a conformational state regulated by the aspartate-phenylalanine-glycine (DFG)-motif[17, 18] (Fig. 1A)[17, 18 17, 18 17, 18 17, 18 17, 18 17, 18]. In the inactive, 'DFG-out' conformational state the directions of DFG-Asp and DFG-Phe 'flip', vacating a pocket previously occupied by DFG-Phe ('DFG-pocket') that modulates binding to type-II inhibitors. A key challenge of targeting kinases in the DFG-out conformation with structure-based virtual screening is that few kinase structures have been reported with the DFG-out conformation[19]. We have recently developed DFGmodel[10], a computational method for modeling kinases in DFG-out conformations. This method informed the mechanism of clinically relevant multi-kinase inhibitors that target the MTC network[15].

In this study, we report the development of an integrated platform (Fig. 2) that combines (i) computational modeling of kinases in their inactive state plus massive multi-target virtual screenings with (ii) whole animal *Drosophila* assays to discover previously unappreciated chemicals that perturb the RET-dependent transformation. Furthermore, we leverage these insights to create a novel 'hybrid' molecule with unique chemical structure and biological efficacy. Finally, we discuss the relevance of this approach to expedite the discovery of novel chemical scaffolds targeting disease networks.

RESULTS

Target selection from fly genetic screen and structural analysis. In transgenic *patched-GAL4;UAS-dRet*^{M955T} (*ptc>dRet*^{M955T}) flies, the *ptc* promoter drives expression of an oncogenic isoform of *Drosophila* Ret in multiple tissues; the result is lethality prior to adult eclosion[1, 15]. We previously used this and similar fly MTC models in genetic screens to identify 104 kinases that mediate *dRet*^{M955T}–mediated transformation[15] (Figs. 1B, 2A, S1).

To narrow this list, we prioritized candidates based on two considerations: (i) pharmacological relevance – kinases downstream of RET signaling were prioritized due to their established functional role[6, 20]; (ii) structural coverage – kinases with known DFG-out structures or those that can be modeled with sufficient accuracy in this conformation were further investigated[10]. Atypical kinases (*e.g.*, mTOR and eEF2K) and members of the RGC family were excluded as they have diverse sequence and structure features that limit our ability to generate accurate homology models. Applying these criteria to our genetic modifier list, we focused on targeting four key kinase targets: RET (receptor tyrosine kinase), SRC (tyrosine kinase), BRAF (tyrosine kinase-like), and p70-S6K (AGC family).

Modeling kinases in DFG-out conformation. Description of the various conformations adopted by the kinases during activation and inhibition is needed for rationally designing novel, conformation-specific inhibitors. Therefore, our approach was to perform massive structure-based virtual screenings of purchasable compound libraries against multiple models with DFG-out conformation; our goal was to identify generic kinase inhibitors that may target one or more prioritized kinases – but more importantly – have an effect on the disease pathway in the animal model.

The structure of two of the kinases identified in our *dRet*^{M955T} model—BRAF and SRC—have been solved in the DFG-out conformation; the DFG-out structures of RET and p70-S6K have not been reported. We therefore generated DFG-out models using DFGmodel, a computational tool that generates homology models of kinase in DFG-out conformation through multiple-template modeling that samples a range of relevant conformations[10]. These models enrich known type-II inhibitors among a diverse set of non-

type-II KIs found in PDB with accuracy similar to or better than that obtained for experimentally determined structures and provides approximation for binding site flexibility[10]. For example, in a recent application of DFGmodel, models generated by this method were used in parallel with medicinal chemistry to optimize clinically relevant compounds that are based on the established kinase inhibitor sorafenib[15]. Conversely, in this study, models generated by DFGmodel are used to develop compounds that are outside of the current kinase inhibitor chemical space.

To guide the identification of a "generic" kinase inhibitor of a disease pathway, we first compared the DFG-out models of the kinases, identifying key similarities and differences in physicochemical properties among their inhibitor-binding sites. First, we noted that the prioritized targets RET, BRAF, p70-S6K, and SRC present negative electrostatic potential on the DFG-pocket surface, while many non-targets such as ERK have positive electrostatic potential (Fig. 3A). This difference may partially explain the partial selectivity of type-II inhibitors (*e.g.*, sorafenib) toward our prioritized targets but not on electrostatic positive kinases such as ERK. Second, RET and SRC have large DFG-pocket volumes (163 $Å^3$, 196 $Å^3$); p70-S6K and BRAF have moderately large pockets (158 $Å^3$, 136 $Å^3$). In contrast, ERK has a small DFG-pocket (113 $Å^3$) (Fig. 3B). We used this size difference to computationally select for kinases with larger DFG-pockets (e.g., RET, SRC) while excluding kinases with smaller DFG-pockets (*e.g.*, ERK).

Virtual screening against MTC pathway. We performed virtual screening against multiple DFG-out models of MTC targets to identify putative small molecules that modulate the disease network (Fig. 2C). We docked a purchasable lead-like library from the ZINC database[21] (2.2 millions compounds) against 10 DFG-out models for each kinase target, yielding over 88 million total docking poses. To combine the screening results, a two-step consensus approach was used. In the first step, compounds that ranked in the top 10% in 5 or more of the 10 models of each kinase were selected, resulting in approximately 2,000 compounds per kinase. In the second step, compounds that ranked in the top 25% in at least 3 of 4 targets were selected, resulting in 247 compounds. For comparison, sorafenib, an inhibitor that rescues *ptc>dRet*^{M955T} flies, would rank eighth in this consensus docking result. From these consensus compounds, eight commercially available compounds were purchased to test their ability to rescue *ptc>dRet*^{M955T} flies (Table S1). These

compounds were selected based on their interactions with key elements of the "ensemble" of targets' binding sites, with the emphasis on the conserved glutamate in αC-helix, the amide backbone of DFG-aspartate, and if present, the amide backbone of the hinge region (Fig. S3) Although the compounds are not predicted to bind optimally to each one of our targets, we hypothesized that these compounds may have an additive effect on the disease pathway, which could be improved with medicinal chemistry.

Testing candidates in ptc>dRet^{M955T} fly viability assay. Transgenic *ptc>dRet^{M955T}* flies express the oncogenic *Drosophila* dRet^{M955T} isoform in several tissues in the developing fly, leading to transformation of dRet^{M955T} tissues[6, 14]. As a result, *ptc>dRet^{M955T}* flies exhibited 0% adult viability when cultured at 25°C, providing a quantitative 'rescue-from-lethality' assay to test drug efficacy[1, 15]. Compounds were fed at the highest accessible concentrations (see Experimental Procedures). We used sorafenib as a positive control, as it previously demonstrated the highest level of rescue among FDA-approved KIs in *ptc>dRet^{M955T}* flies[15]. Similar to our previous results, feeding *ptc>dRet^{M955T}* larvae sorafenib (200 μM) improved overall viability to 3-4% adult survival ($P < 0.05$).

We used this rescue-from-lethality assay to test the efficacy of the eight compounds identified through virtual screening (Figs. 4B, 5B). When fed orally, two unique compounds, ***1*** and ***2*** (Table S2), rescued a small fraction of *ptc>dRet^{M955T}* flies to adulthood (Figs. 4A and 5A) and did not affect the body size of the larvae and pupae, a metrics for comparing food intake, of *ptc>dRet^{M955T}* flies when compared to the wild-type. At the maximum final concentration in fly food (100 μM), ***1*** rescued 1% ($P < 0.05$) *ptc>dRet^{M955T}* flies to adulthood as compared to 3-4% rescue by sorafenib at 200 μM (Fig. 4A). ***1*** is characterized by the 3-phenyl-(1*H*)-1,2,4-trazole moiety (Fig. 4B). ***2***, characterized by the 1*H*-indole-2-carboxamide moiety, improved *ptc>dRet^{M955T}* fly viability to an average of 1% ($P < 0.05$) when tested at 25-400 μM (Fig. 5A,B).

Confirmation of novel chemical scaffolds. To validate the chemical scaffolds identified in our initial *Drosophila*-based chemical genetic screening, we conducted a ligand-based chemical similarity search in the updated ZINC[8] to identify analogs of ***1*** and ***2***. For compound ***1***, we retrieved five compounds that share the 3-phenyl-(1*H*)-1,2,4-triazole feature

185 and have docking poses similar to ***1***. Our *ptc>dRet*^{M955T} screen confirmed two active com-
186 pounds, ***1-1*** and ***1-2*** (Table S2; Fig. 4A, 4B). ***1-1*** outperformed ***1*** slightly in *ptc>dRet*^{M955T}
187 fly rescue at similar concentrations (4%; $P < 0.05$). Conversely, ***1-2*** was tested at higher
188 concentrations (50 and 200 μM) but did not result in better efficacy ($P < 0.05$).

189 The docking poses of ***1-1*** and ***1-2*** resemble the proposed docking pose of ***1*** (Fig.
190 4B), which has a typical DFG-out-specific, type-II KI binding pose and is predicted to oc-
191 cupy the DFG-pocket with the terminal phenyl moiety. The 1,2,4-triazole moiety, resem-
192 bles the urea moiety found in sorafenib (Fig. 1A), forms favorable hydrogen bonds with
193 the side chain of the conserved αC-helix glutamate residue and the backbone amide of
194 the DFG-Aspartate. In addition, this series of compounds are smaller and shorter (MW <
195 360) than the fully developed type-II KIs (MW > 450) such as sorafenib, as they lack an
196 optimized moiety that interacts with the hinge region of the ligand-binding site (Fig. 4C).

197 Compound ***1-2*** differs from ***1*** and ***1-1*** structurally and was less effective in rescuing
198 *ptc>dRet*^{M955T} flies, even though it was tested at higher concentrations (Fig. 4A). While ***1***
199 and ***1-1*** have an (1*H*)-1,2,4-triazole moiety, ***1-2*** has an 1,2,4-oxadiazol-5-amine moiety,
200 where the (1*H*)-nitrogen is replaced by an oxygen. This modification distinguishes ***1-2***
201 from ***1*** and ***1-1*** in their interaction preference: ***1-2*** loses a hydrogen bond donor due to
202 the nitrogen-to-oxygen substitution, while the electronegative oxygen introduces an unfa-
203 vorable electrostatic repulsion to the carboxylate sidechain of the conserved αC-helix glu-
204 tamate (Fig. 4C, ***1-2*** insert).

205 Co-administering sorafenib with ***1*** and ***1-1*** led to synergistic improvement of
206 *ptc>dRet*^{M955T} fly viability (Fig. 4A). Individually, 200 μM of sorafenib and 100 μM of ***1***
207 rescued 3% and 1% of *ptc>dRet*^{M955T} flies to adulthood, respectively. Co-administering
208 the two compounds rescued 6% of *ptc>dRet*^{M955T} flies to adulthood ($P < 0.05$). Similarly,
209 co-administering sorafenib and 100 μM of ***1-1*** rescued 8% of *ptc>dRet*^{M955T} flies ($P <$
210 0.05). In contrast, co-administering 200 μM of sorafenib and 200 μM of ***1-2*** did not im-
211 prove fly viability. As ***1-2*** only weakly rescued *ptc>dRet*^{M955T} flies and showed no synergy
212 with sorafenib, we did not pursue this hit any further.

213 We examined the kinase inhibition profile (DiscoverX) of ***1*** against a subset of the
214 human protein kinome (Table 1). At 50 μM, ***1*** did not appreciably inhibit SRC, BRAF, or

S6K1, while it demonstrated weak activity against wild-type RET and moderate activity against the oncogenic isoform RET^{M918T}. Of note, ***1*** inhibited other cancer-related targets such as FLT3 (Table 1), which activates the Ras/ERK signaling pathway[22].

1 also showed activity against aspects of transformation and metastasis in the fly. In the mature larva, the *ptc* promoter is active in epithelial cells in a stripe pattern in the midline of the developing wing epithelium (Fig. 4C; wing disc). *ptc*-driven dRet activates multiple signaling pathways, promoting proliferation, epithelial-to-mesenchymal transition (EMT), and invasion of $dRet^{M955T}$-expressing cells beyond the *ptc* domain[14] (Fig. 4C). Similar to sorafenib, oral administration of ***1*** blocked the invasion of $dRet^{M955T}$-expressing cells into the surrounding wing epithelium (Fig. 4B).

At lower dosage (25 μM), compound ***2*** weakly rescued $ptc>dRet^{M955T}$ flies (1%; $P < 0.05$) (Fig. 5A). Unlike ***1***, ***2*** did not act synergistically with sorafenib. This difference was confirmed by the kinase inhibition profile of ***2*** (Table 2), in which it has stronger inhibition of RET and RET^{M918T}, but loses the inhibition of FLT3, two key differences between the kinase inhibition profiles of ***1*** and ***2***.

Through a chemical similarity search of the ZINC database, we identified five compounds that share the 1*H*-indole-2-carboxamide moiety with docking poses similar to that of ***2*** (Fig. 5B, 5C; Table S2), and confirmed all five analogs were able to improve the viability of $ptc>dRet^{M955T}$ flies (Fig. 5A), albeit with weak efficacy (some have *P*-value above 0.05). At low dose (10 μM), ***2-1*** showed improved efficacy in rescuing $ptc>dRet^{M955T}$ flies relative to ***2*** and had similar efficacy as sorafenib at 200 μM. However, ***2-1*** showed poor solubility, limiting its usefulness as lead compound. ***2-3*** was also more efficacious than ***2*** and displayed better solubility in both DMSO and water than ***2-1***; it also has the *N*-phenylacetamide moiety as a linker group, a common linker feature found in type-II KIs such as imatinib. Compound ***2-3*** displayed a different inhibition profile than ***1*** and ***2*** (Table 2): it strongly inhibits FLT3 and PDGFRB, though is weak against both RET and RET^{M918T} and does not inhibit SRC.

Improving efficacy through compound hybridization. Interestingly, the chemical scaffolds of our newly identified active compounds are not associated with inhibition of protein kinases, as the analysis with SEA search[23] — which relates ligand chemical similarity of

ligands to protein pharmacology — suggests. However, they provide rescue of *ptc>dRet*^{M955T} flies similar to that of sorafenib and regorafenib[15]. The docking poses of these compounds suggest a less-than-optimal interaction with the hinge region of protein kinases, a common feature of most KIs. Furthermore, the relatively low molecular weight (~350 g/mol) of these lead-like compounds provides a window for conducting lead optimization with medicinal chemistry. Hence, we sought to improve the efficacy of our computationally derived leads by installing a hinge-binding moiety found in known type-II KIs such as sorafenib.

We took into consideration the docking poses and phenotypic results of the known type-II kinase inhibitors (sorafenib and AD80[1]) and lead compounds, as well as the synthetic accessibility and the novelty of the putative hybrid compounds, even if they do not dock optimally to our intended kinase targets. We focused on the functionalization of ***2***/***2-3*** based on these observations: 1) their 1*H*-indole moiety docks uniquely into the DFG-pocket and with the potential to interact with the αC-helix glutamate (Fig. 5C), 2) their 1*H*-indole-2-carboxamide moiety resembles the urea linker that is commonly found in type-II KIs such as sorafenib (Fig. 6A; blue box), and 3) the *N*-phenylcarboxamide moiety of ***2-3*** is a common linker between the hinge-binding and the DFG-pocket moieties of type-II KIs, e.g. imatinib (Fig. 6A; grey box), while the *N*-(piperidin-4-yl)carboxamide moiety of ***2*** is not a common linker, and 4) docking pose of ***2***/***3***'s 1H-indole moiety overlaps with the trifluoromethylphenyl moiety of sorafenib/AD80. We performed a fragment exchange at the carboxamide position by combining the 1*H*-indole-2-carboxamide moiety of ***2/2-3*** with the hinge-binding moiety of sorafenib and of AD80, a multi-kinase inhibitor that has shown promise in MTC treatment[1], to create ***3*** and ***4***, respectively (Fig. 6B).

Oral administration of ***3*** and ***4*** to *ptc>dRet*^{M955T} flies demonstrated that the efficacy of ***4*** was low with only 3% rescue, while ***3*** demonstrated much improved efficacy with 15% rescue (Fig. 6C; $P < 0.05$), significantly higher rescue than the parent compound ***2/2-3*** and sorafenib. Additionally, ***3*** suppressed the invasion/migration of dRet^{M955T}-expressing cells in the wing epithelium (Fig. 6D), further confirming its efficacy against dRet^{M955T}–induced oncogenicity. The kinase inhibition profile of ***3*** (Table 3) resembles that of the parent compound ***2-3*** (Table 2) with at least two notable exceptions: ***3*** inhibits

CSF1R, PDGFRB, and FLT3, all are receptor tyrosine kinases and orthologs of *Drosophila* Pvr that activate the Ras/ERK signaling pathway[24] and play key roles in SRC activation and tumor progression; and the inhibition of Aurora kinases AURKB and AURKC (*Drosophila* ortholog aurA or aurB). Of note, although ***4*** did not improve the viability of *ptc>dRet*^{M955T} flies, it shares chemical similarity to several known type-I1/2 kinase inhibitors that have the common adenine moiety and a related indole moiety. This group of inhibitors was shown to inhibit other related kinases, increasing our confidence in the relevance of this chemical space for kinase pathway modulation[25].

DISCUSSION

Integrated discovery pipeline. This study demonstrates the utility of an integrated platform that combines *Drosophila* genetics, computational structural biology, and chemical synthesis to enrich for the discovery of useful chemical tools in an established *Drosophila* MTC model (Fig. 2). We have previously shown that *Drosophila* can provide a unique entry point for drug development, by capturing subtle structural changes in lead compounds that are often missed by cellular or biochemical assays. Here we refine this approach by iteratively combining experimental testing with computational modeling. Overall, a key strength of the combined approach is its ability to rapidly and in a cost-effective manner test chemically unique, purchasable compounds with our fly models; this platform allowed us to quickly confirm the *in situ* relevance of active chemotypes through iterations of computational modeling, synthetic chemistry, and phenotypic testing in the fly. We expect this integrated pipeline is generally applicable to kinase networks associated with other diseases[7].

DFG-out modeling approach. DFGmodel is a recent computational development that generates models of kinases in their inactive, DFG-out conformation for rational design of type-II KIs[10]. In a recent study, models generated by DFGmodel were used to guide the optimization of the drug sorafenib, to target a new disease space[15]. Here, we demonstrated a successful application of DFGmodel to explore compounds that are not appreciated as kinase inhibitors. For each kinase target, DFGmodel uses multiple experimentally determined structures as modeling templates and generates multiple homology models. Thus, this method samples a large fraction of the DFG-out conformational space during the model construction, which enables us to account for the flexibility of the binding site during virtual screening[26]. Notably, DFG-out models capture key features that are important for protein-ligand interactions in multiple kinases simultaneously, providing a framework for rationalizing activity of known inhibitors and developing unique KIs that target a signaling pathway. For example, our results suggest that the electrostatic potential within the DFG-pocket is a key feature for inhibitor selectivity: ERK has an inverse electrostatic potential in the DFG-pocket than that of the target kinases such as RET and

BRAF (Fig. 3), which may explain the insensitivity of ERK toward inhibitors such as sorafenib.

Identification of biologically active compounds. Most clinically approved KIs are ineffective against MTC; the most effective inhibitors, sorafenib and regorafenib, show limited efficacy in the *ptc>dRet*^{M955T} fly model, rescuing only 3-4% at 200 μM[15]. Despite considerable academic and industry effort, the known chemical space of kinase inhibitors is limited[7]. For example, sorafenib and regorafenib differ in only one non-hydrogen atom. Through structure-based virtual screening against multiple kinase targets in a disease pathway, we discovered chemically unique, low molecular-weight compounds (Table S2) with a *ptc>dRet*^{M955T} rescue rate similar to that of sorafenib (Figs. 4 and 5).

Importantly, our data indicates that these compounds act through key cancer networks. For example, compounds ***1***, ***2***, ***2-3*** and ***3*** all have shown the ability to suppress invasion of *ptc>dRet*^{M955T}cells in the wing epithelium. Previous works demonstrated that wing cell invasion is mediated by SRC[15, 27], which acts by controlling E-cadherin and Matrix Metalloproteases (MMPs). Of note, ***1***, ***2***, ***2-3*** and ***3*** each show significant activity against orthologs of *Drosophila* Pvr, a key regulator of Src: all show significant activity against human FLT3, while ***3*** shows additional activity against Pvr orthologs CSF1R and PDGFRB. In addition to being orthologs of Pvr, FLT3, CSF1R, and PDGFRB similarly can activate SRC[28]. We propose that this activity against regulators of SRC account for the ability of ***1***, ***2***, ***2-3*** and ***3*** to suppress invasion, a key first step in tumor metastasis. Other activities, for example, ***3***'s inhibition of Aurora kinases — required for proliferation during tumor progression[29] — likely also contributes. Indeed, AURK inhibitors are known to be active against MTC[30, 31] and synergy between AURKs and FLT3 is currently being explored clinically through a number of dual-AURKB/FLT3 inhibitors[32 33].

Recombination of building blocks for future inhibitors. Though the new tool compounds ***1*** and ***2*** may not be sufficiently potent to serve as therapeutics, they reveal diverse fragment-like pharmacophores that serve as starting points for an exploration of new chemical space. These pharmacophores can be further optimized by combining with well-developed chemotypes that are known to interact with kinase binding sites (e.g., the hinge binding region) to form more efficacious chemical probes; this provides a key second step

342 towards building effective compounds. For example, ***2*** and ***2-3*** include an 1*H*-indole moi-
343 ety capable of occupying the DFG-pocket of protein kinases from different families and a
344 carboxamide group commonly found in type-II KIs (Fig. 6A). Guided by the docking poses
345 of these compounds, the 1*H*-indole-2-carboxamide group was combined with an opti-
346 mized hinge-binding moiety from sorafenib, to form a significantly more efficacious com-
347 pound (i.e., ***3***). As indicated in the kinase inhibition profile of ***3*** (Table 3), it shares part of
348 the target set of its constituents ***2*** and ***2-3***.

349 In summary, we demonstrate the potential of combining chemical modeling with
350 *Drosophila* genetics to rapidly and efficiently explore novel chemical space. This provides
351 an accessible and cost-effective platform that can be applied to a broad palette of dis-
352 eases that can be modeled in *Drosophila.* Combining the strengths of these two high-
353 throughput approaches opens the opportunity to develop novel tool and lead compounds
354 that are effective in the context of the whole animal.

355

EXPERIMENTAL PROCEDURES

DFG-out models. Models of kinase targets (human RET, SRC, BRAF, S6K1) in the DFG-out conformation were generated using DFGmodel[10]. Briefly, the method takes a DFG-in structure or the sequence of the protein kinase as input. DFG-model relies on a manually curated alignment between the target kinase and multiple structures representing unique DFG-out conformations. It calls on the structure-based sequence alignment function of T_COFFEE/Expresso[34] v11.00.8 to perform sequence alignment of the kinase catalytic domain to the templates, followed by the multi-template function of MODELLER[35] v9.14 to generate 50 homology models covering a range of conformations. For each kinase 10 DFG-out models with largest binding site volume, as calculated by POVME[36] v2.0, were used for further study. These ensembles of models were evaluated and confirmed to enrich known type-II inhibitors over non-ligands using docking, which provides an approximation of the binding site flexibility, as well as optimizes the binding site for protein-ligand complementarity and structure-based virtual screening[11, 26, 37]. The area-under-curve (AUC) of targets BRAF and RET DFG-out models are 90.6 vs. 82.8, respectively, which correspond to at least 5-fold increase in the enrichment accuracy over randomly selected ligands in a known sample set[37, 38, 39].

Virtual screening. Initial virtual screening utilized the ZINC12[21] "available now" lead-like chemical library (downloaded in 2013, 2.2 million compounds). Default settings were used for the ligand conformer generation with OMEGA and the docking program FRED[40]. For each kinase, the ensemble of 10 DFG-out models was used for screening and the results were processed with the open-source cheminformatics toolkit RDKit (www.rdkit.org). To obtain a consensus docking result for RET and the targets BRAF, SRC, p70-S6K, a two-step approach was used: 1) 2,000 ligands were collected for each kinase by identifying ligands that ranked in the top 10% for at least half of the DFG-out ensemble.; 2) ligands that scored in the top 25% in at least 3 of 4 kinase ensembles were collated into a final set of 247 compounds. These consensus ligands, representing 0.0114% of the library, were visually inspected to remove molecules with energetically unfavorable or strained conformations, or with reactive functional groups that may interfere with assays[41], which are commonly observed in large virtual screenings. 8 compounds were selected based

386 on their interactions with the receptor (DFG-pocket occupancy, hydrogen-bond to con-
387 served amino acids, etc) and chemical novelty and were purchased for *Drosophila* viabil-
388 ity screening. Analogs ***1-1***, ***1-2***, ***2-1 to 2-5***, and others (Table S1) were identified based
389 on the structure of compounds ***1*** and ***2*** through the chemical similarity search function
390 available in ZINC15[8] and SciFinder using the default setting and Tanimoto coefficient
391 above 70%. These compounds are commercially available through vendors such as
392 ChemBridge and Enamine.

393 ***Chemical Methods.*** For synthetic procedures and characterization data related to com-
394 pounds ***1***, ***3***, and ***4***, please see supplementary materials.

395 ***Kinase profiling of compounds.*** Kinase inhibition profile of the compounds was as-
396 sessed at 50 μM through commercially available kinase profiling services (DiscoverX).

397 ***Drosophila stocks.*** Human orthologs of *Drosophila* genes were predicted by DIOPT
398 (http://www.flyrnai.org/cgi-bin/DRSC_orthologs.pl). The multiple endocrine neoplasia
399 (MEN) type 2B mutant form of *Drosophila* Ret carries the M955T mutation (dRet^{M955T}),
400 which corresponds to the M918T mutation found in human MTC patients. The *ptc-gal4*,
401 *UAS-GFP*; *UAS-dRet^{M955T}/SM5(tub-gal80)-TM6B* transgenic flies were prepared accord-
402 ing to standard protocols[15]. In these flies, the *tubulin* promoter drives GAL80, a suppres-
403 sor of GAL4, to repress dRet^{M955T} expression. We crossed them with *w^{-}* flies to obtain
404 *ptc>dRet^{M955T}* flies that lost *GAL80* allele, which derepressed dRet^{M955T} expression (Fig.
405 S1A). Transgenic *ptc>Ret^{M955T}* flies were calibrated to have 0% survival when raised at
406 25°C, which allowed for drug screening (Fig. S1B).

407 ***Chemical genetic screening in flies***. We employed dominant modifier screening[15] using
408 the *ptc-gal4*, *UAS-GFP*; *UAS-dRet^{M955T}/SM5(tub-gal80)-TM6B* to screen for fly kinase
409 genes that affected the *dRet^{M955T}*-induced lethality in flies when heterozygous
410 (*ptc>Ret^{M955T};kinase$^{-/+}$*). Genes that improved or reduced survival of *ptc>dRet^{M955T}* flies
411 when heterozygous were designated as genetic 'suppressors' or 'enhancers', respec-
412 tively (Fig. 1B). Suppressors are candidate therapeutic targets that when inhibited may
413 reduce tumor progression.

414 Stock solutions of the test compounds were created by dissolving the compound in DMSO
415 at the maximum concentration. The stock solutions were diluted by 1000-fold or more and

416 mixed with semi-defined fly medium (Bloomington Drosophila Stock Center) to make
417 drug-infused food (0.1% final DMSO concentration; maximum tolerable dose in flies). Ap-
418 proximately 100 *ptc>dRet*^{M955T} embryos alongside with wild-type (*+;+/SM5*$_{tubgal80}$*-TM6B*)
419 flies were raised until adulthood on drug-infused food for 13 days at 25°C. The numbers
420 of empty pupal cases (*P* in Fig. S1B) and that of surviving adults (*A*) were used to deter-
421 mine percentage of viability, while their body size, which is affected by food intake, tem-
422 perature, and humidity, were compared to vehicle-treated groups to standardize the ex-
423 perimental conditions.

424 ***Wing discs cell migration/invasion assays.*** Third-instar *ptc>dRet*^{M955T} larvae were dis-
425 sected, and developing wing discs were collected, fixed with 4% paraformaldehyde in
426 PBS, and whole-mounted. At least 10 wing discs were analyzed for each treatment. In-
427 vasive GFP-labeled dRet^{M955T}-expressing cells were visualized by their green pseudo-
428 color under a confocal microscope. The apical and the virtual z-series views of the wing
429 disc were examined to identify abnormal tissue growth and dRet^{M955T}-expressing cells
430 migrating beyond the *ptc* domain boundary.

431

432

ACKNOWLEDGEMENTS

We thank Peter Smibert (New York Genome Center) for *ptc>dRet*^{M955T} flies, Kevin Cook (Bloomington *Drosophila* Stock Center) for kinome mutant fly lines. This work was supported by the National Institutes of Health (R01-GM108911) to A.S. and P.M.U.U. A.S. was also supported by Department of Defense grant W81XWH-15-1-0539. M.S. and R.C. were supported by National Institutes of Health grants U54OD020353, R01-CA170495, and R01-CA109730 and Department of Defense grant W81XWH-15-1-0111. The Dar laboratory (A.P.S. and A.C.D.) is supported by Innovation awards from the NIH (DP2 CA186570-01) and Damon Runyon-Rachleff Foundation. A.C.D. is a Pew-Stewart Scholar in Cancer Research and Young Investigator of the Pershing-Square Sohn Cancer Research Alliance. We appreciate OpenEye Scientific Software, Inc. for granting us access to its high-performance molecular modeling applications through its academic license program. This work was supported in part through the computational resources and staff expertise provided by the Department of Scientific Computing at the Icahn School of Medicine at Mount Sinai.

AUTHOR CONTRIBUTIONS

P.M.U.U. performed and analyzed the homology modeling of kinases, virtual screening of compound library, selection and design of testing compounds. M.S. managed *Drosophila* stocks and testing compounds in whole animal and *in vivo* experiments. A.P.S. conducted organic synthesis, design, and validation of test compounds. P.M.U.U. analyzed results and wrote the manuscript with input from all co-authors. R.L.C., A.C.D., and A.S. initiated, supervised, and acquired funding and resources for the project.

COMPETING FINANCIAL INTERESTS

None.

FIGURE LEGENDS



Figure 1. Kinase binding to type-II kinase inhibitors. ***(A)*** The conformational state of protein kinases (e.g., KDR) including DFG-in (red) and DFG-out (blue) is determined by the DFG-motif. The DFG-pocket (cyan mesh) is unique to the DFG-out conformation. Sorafenib is shown in pink. Broken yellow lines indicate hydrogen bonds. ***(B)*** A scheme depicting the positive and negative effects of drug acting on genetic modifiers of medullary thyroid cancer in a *Drosophila* model. *ptc*-driven *dRet*^{M955T} induces lethality during development. 'Suppressors' or 'enhancers' suppress or enhance, respectively, *dRet*^{M955T}-induced disease phenotypes as revealed in genetic screening. A drug can suppress lethality by inhibiting the suppressors. It can also induce toxicity and/or worsen transformed phenotypes by inhibiting the enhancers, which results in enhanced lethality.



Figure 2. Fly genetics and computational chemistry discovery platform. Key steps include **(A)** determining suppressors and enhancers in a dominant modifier genetic screening and their *in silico* modelability, **(B)** generating DFG-out kinase models using DFGmodel, **(C)** virtual screenings of compound libraries against the modeled suppressors and enhancers, combining top-ranking screening results into consensus result, **(D)** testing top-ranking compounds for rescue of lethality (left panel) and migration of transformed cells in developing wing discs of *ptc>dRet*^{M955T} flies (right panel), and **(E)** refining hits by combining structural elements of computationally derived hits and that of drugs and evaluating new targets.



Figure 3. Visualization of DFG-pockets. (A) Electrostatic potential (red, negative potential; blue, positive potential) on the surface of the DFG-pocket in various kinases, including the suppressors RET and SRC, the enhancer TTK, and ERK. **(B)** Accessible volume of the DFG-pocket (colored volume) for potential type-II kinase inhibitor. Hit molecule ***1*** is depicted in pink sticks. Broken yellow lines indicate hydrogen bonds.



Figure 4. Compound *1* and its analogs. (A) Rescue of *ptc>dRet*^{M955T} fly lethality by ***1*** and ***1-1***. Both showed improved efficacy (synergy) when co-administrated with 200 μM sorafenib (soraf). (-), vehicle DMSO control. Error bars represent standard error in triplicate experiments. *$P < 0.05$ in one-sided Student's *t*-test as compared with vehicle control. **(B)** Docking pose of ***1*** and its analogs ***1-1*** and ***1-2*** (salmon sticks) with a DFG-out model of RET (broken yellow lines indicate hydrogen bonds), and their inhibition of migration of the dRet^{M955T}-expressing cells. Right, suppression of cell migration by ***1*** and ***1-1***. Controls are shown in (C). **(C)** *In vivo* cell migration assay in *ptc>dRet*^{M955T} flies. Left, a developing whole wing disc containing GFP-labeled, dRet^{M955T}-expressing cells constituting a stripe in the midline. The disc margin is visualized with DAPI (red pseudocolor). There are wild-type cells in black areas. Center, overgrowth of dRet^{M955T}-expressing cells resulting in the thickening of the stripe in the apical view (top). In the z-series view (bottom), dRet^{M955T}-expressing cells are migrating away from the original domain (arrows). Right, sorafenib suppressed the migration.



510

511 **Figure 5. Rescue of *ptc>dRet*^{M955T} flies by *2* and its analogs. (A)** *ptc>dRet*^{M955T} viabil-
512 ity assay. ***2*** showed increased efficacy when co-administrated with 200 μM sorafenib. (-
513), vehicle control. Error bars represent standard error in triplicate experiments. *$P < 0.05$
514 in one-sided Student's *t*-test as compared with no-drug control. **(B)** Chemical structure of
515 ***2*** and its analogs. **(C)** Docking pose of ***2*** and its analogs in a RET DFG-out model. These
516 compounds are proposed to be putative type-II kinase inhibitors that bind in the DFG-
517 pocket through their 1*H*-indole moiety and interact with the conserved αC-helix glutamate
518 side chain and DFG-Aspartate backbone (broken yellow lines).

519

520



Figure 6. Hybrid compounds with improved efficacy. (A) The kinase inhibitors imatinib, sorafenib, and ***2-3*** share the common *N*-phenylcarboxamide moiety (grey box), while the 1*H*-indole-2-carboxamide of ***2-3*** resembles the urea linker of sorafenib (blue box). **(B)** Hybridization of ***2*** and sorafenib and AD-80 yielded ***3*** and ***4***, respectively. Top, chemical structures of compounds. Bottom, docking poses of compounds in a RET DFG-out model. **(C)** ***3*** rescued *ptc>dRet*^{M955T} flies more effectively than by either ***2*** or sorafenib alone. (-), vehicle control. Error bars represent standard error in triplicate experiments. **P* < 0.05 in one-sided Student's *t*-test as compared with no-drug control. **(D)** ***3*** suppresses migration of dRet^{M955T}-expressing wing disc cells from the original domain (green) similarly to the positive control, sorafenib. Top and bottom, apical and z-series views, respectively. Arrows, migrating cells.

535 **TABLES**

536

Table 1. Kinase inhibition profile of compound ***1*** at 50 μM.

Kinase	% Inhib.	Kinase	% Inhib.
ABL1	0	mTOR	4
AURKA	22	PDGFRB	21
AURKB	7	RET	15
AURKC	2	RET (M918T)	28
BRAF	9	RET (V804L)	35
CSF1R	3	S6K1	0
FGFR	0	SRC	5
FLT3	**52**	TTK	17

537 Bold, inhibited by more than 40%.

538

Table 2. Kinase inhibition profile of compounds ***2*** and ***2-3*** at 50 μM.

Compound ***2***				Compound ***2-3***			
Kinase	% Inhib.	Kinase	% Inhib.	Kinase	% Inhib.	Kinase	% Inhib.
ABL1	0	mTOR	5	ABL1	2	mTOR	8
AURKA	10	PDGFRB	20	AURKA	13	PDGFRB	**91**
AURKB	2	RET	34	AURKB	22	RET	24
AURKC	22	**RET (M918T)**	**44**	AURKC	2	RET (M918T)	23
BRAF	0	**RET (V804L)**	**44**	BRAF	0	**RET (V804L)**	**43**
CSF1R	12	S6K1	0	CSF1R	20	S6K1	0
FGFR	0	SRC	6	FGFR	4	SRC	0
FLT3	25	TTK	31	**FLT3**	**78**	TTK	26

539 Bold, inhibited by more than 40%.

540

541

Table 3. Kinase inhibition profile of compound ***3*** at 50 μM.

Kinase	% Inhib.	Kinase	% Inhib.
ABL1	0	mTOR	4
AURKA	15	**PDGFRB**	**98**
AURKB	**88**	RET	29
AURKC	**91**	RET (M918T)	26
BRAF	4	**RET (V804L)**	**46**
CSF1R	**95**	S6K1	0
FGFR	0	SRC	4
FLT3	**80**	TTK	27

542 Bold, inhibited by more than 40%.

543

REFERENCES

1. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. *Nature* **486**, 80-84 (2012).

2. Kasai Y, Cagan R. Drosophila as a tool for personalized medicine: a primer. *Personalized medicine* **7**, 621-632 (2010).

3. Sonoshita M, Cagan RL. Modeling Human Cancers in Drosophila. *Curr Top Dev Biol* **121**, 287-309 (2017).

4. Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. *Cancer research* **65**, 3538-3541 (2005).

5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science* **298**, 1912-1934 (2002).

6. Read RD, Goodfellow PJ, Mardis ER, Novak N, Armstrong JR, Cagan RL. A Drosophila model of multiple endocrine neoplasia type 2. *Genetics* **171**, 1057-1081 (2005).

7. Schlessinger A, Abagyan R, Carlson HA, Dang KK, Guinney J, Cagan RL. Multi-targeting Drug Community Challenge. *Cell Chem Biol* **24**, 1434-1435 (2017).

8. Sterling T, Irwin JJ. ZINC 15--Ligand Discovery for Everyone. *Journal of chemical information and modeling* **55**, 2324-2337 (2015).

9. Irwin JJ, Shoichet BK. Docking Screens for Novel Ligands Conferring New Biology. *Journal of medicinal chemistry* **59**, 4103-4120 (2016).

10. Ung PMU, Schlessinger A. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors. *ACS chemical biology* **10**, 269-278 (2015).

11. Abagyan R*, et al.* Accurate ligand docking and screening: Lessons from the Pocketome. *Abstr Pap Am Chem S* **245**, (2013).

12. Cerrato A, De Falco V, Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. *Journal of molecular endocrinology* **43**, 143-155 (2009).

13. Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. *The lancet Diabetes & endocrinology* **4**, 64-71 (2016).

14. Vidal M, Larson DE, Cagan RL. Csk-deficient boundary cells are eliminated from normal Drosophila epithelia by exclusion, migration, and apoptosis. *Developmental cell* **10**, 33-44 (2006).

15. Sonoshita M*, et al.* A whole-animal platform to advance a clinical kinase inhibitor into new disease space. *Nature chemical biology* **14**, 291-298 (2018).

16. Wan PT*, et al.* Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. *Cell* **116**, 855-867 (2004).

17. Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. *Structure* **15**, 299-311 (2007).

18. Huse M, Kuriyan J. The conformational plasticity of protein kinases. *Cell* **109**, 275-282 (2002).

19. Zhao Z*, et al.* Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? *ACS chemical biology* **9**, 1230-1241 (2014).

20. Mulligan LM. RET revisited: expanding the oncogenic portfolio. *Nature reviews Cancer* **14**, 173-186 (2014).

21. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. *Journal of chemical information and modeling* **52**, 1757-1768 (2012).

22. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. *Semin Oncol* **35**, 336-345 (2008).

23. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. *Nat Biotechnol* **25**, 197-206 (2007).

24. Schlessinger J. Cell signaling by receptor tyrosine kinases. *Cell* **103**, 211-225 (2000).

25. Burchat A, Borhani DW, Calderwood DJ, Hirst GC, Li B, Stachlewitz RF. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. *Bioorganic & medicinal chemistry letters* **16**, 118-122 (2006).

26. Amaro RE, Li WW. Emerging methods for ensemble-based virtual screening. *Curr Top Med Chem* **10**, 3-13 (2010).

27. Vidal M, Warner S, Read R, Cagan RL. Differing Src signaling levels have distinct outcomes in Drosophila. *Cancer research* **67**, 10278-10285 (2007).

28. Sachsenmaier C, Sadowski HB, Cooper JA. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. *Oncogene* **18**, 3583-3592 (1999).

29. Sasai K*, et al.* Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. *Cell Motil Cytoskeleton* **59**, 249-263 (2004).

30. Baldini E*, et al.* Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. *BMC Cancer* **11**, 411 (2011).

31. Tuccilli C*, et al.* Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. *Endocrine* **52**, 287-295 (2016).

32. Bavetsias V, Linardopoulos S. Aurora Kinase Inhibitors: Current Status and Outlook. *Front Oncol* **5**, 278 (2015).

33. Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. *Mol Cancer Ther* **9**, 661-672 (2010).

34. Notredame C, Higgins DG, Heringa J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. *Journal of molecular biology* **302**, 205-217 (2000).

35. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *Journal of molecular biology* **234**, 779-815 (1993).

36. Durrant JD, Votapka L, Sorensen J, Amaro RE. POVME 2.0: An Enhanced Tool for Determining Pocket Shape and Volume Characteristics. *Journal of chemical theory and computation* **10**, 5047-5056 (2014).

37. Fan H, Irwin JJ, Webb BM, Klebe G, Shoichet BK, Sali A. Molecular docking screens using comparative models of proteins. *Journal of chemical information and modeling* **49**, 2512-2527 (2009).

38. Katritch V, Rueda M, Lam PC, Yeager M, Abagyan R. GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex. *Proteins* **78**, 197-211 (2010).

39. Carlsson J*, et al.* Ligand discovery from a dopamine D3 receptor homology model and crystal structure. *Nature chemical biology* **7**, 769-778 (2011).

40. OEDOCKING 3.2.0.2: OpenEye Scientific Software, Santa Fe, ME. (ed^(eds).

41. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *Journal of medicinal chemistry* **53**, 2719-2740 (2010).